Investment Rating - The report assigns a "Strong Buy" rating to the company for the first time [5][8]. Core Insights - The company has successfully commercialized its first product, the KRAS G12C inhibitor, and has established a partnership with AstraZeneca for its next-generation pan-KRAS inhibitor, JAB-23E73, which is expected to accelerate global value realization [5][6]. - The company is innovating in the ADC field with tADC and iADC platforms, which aim to overcome traditional treatment limitations and enhance therapeutic efficacy [5][6]. - The financial projections indicate significant revenue growth, with expected revenues of 234 million, 627 million, and 508 million CNY for 2025, 2026, and 2027, respectively, alongside a notable increase in net profit in 2026 [5][8]. Financial Summary - Total revenue (CNY million): 156 in 2024A, 234 in 2025E, 627 in 2026E, and 508 in 2027E, with year-on-year growth rates of 145.1%, 50.5%, 167.6%, and -19.1% respectively [5]. - Net profit attributable to shareholders (CNY million): -156 in 2024A, -15 in 2025E, 313 in 2026E, and 192 in 2027E, with year-on-year growth rates of 56.6%, 90.7%, 2,258.6%, and -38.6% respectively [5]. - Earnings per share (CNY): -0.20 in 2024A, -0.02 in 2025E, 0.40 in 2026E, and 0.24 in 2027E [5]. Market Position and Product Pipeline - The company has a comprehensive pipeline focusing on KRAS and other challenging drug targets, with its first commercial product already contributing to cash flow [6][33]. - The partnership with AstraZeneca for JAB-23E73 is expected to enhance the company's competitive edge in the oncology sector [7][33]. - The company is advancing multiple ADC candidates, including tADC and iADC, which are anticipated to address unmet medical needs in cancer treatment [5][6].

Investment Rating - The report assigns a "Strong Buy" rating to the company for the first time [5][8]. Core Insights - The company has significant potential for value re-evaluation, particularly with its pan-KRAS inhibitors and strategic collaborations, notably with AstraZeneca [5][6]. - The first commercial product, KRAS G12C inhibitor Goleirese, has been approved and is expanding its indications, contributing to cash flow [5][33]. - The next-generation ADC platforms, tADC and iADC, are expected to overcome traditional treatment limitations and enhance the company's competitive edge in oncology [5][6][7]. Financial Summary - Projected total revenue (in million CNY) for 2024A, 2025E, 2026E, and 2027E is 156, 234, 627, and 508 respectively, with year-on-year growth rates of 145.1%, 50.5%, 167.6%, and -19.1% [5][8]. - Expected net profit attributable to shareholders (in million CNY) for the same years is -156, -15, 313, and 192, with growth rates of 56.6%, 90.7%, 2,258.6%, and -38.6% [5][8]. - The estimated price-to-earnings ratio (P/E) for 2026 is 14, and for 2027 is 23, indicating a potential for profitability [5][8]. Product Pipeline and Collaborations - The company has developed a differentiated innovation drug research system targeting difficult drug targets like KRAS, with a focus on pan-KRAS inhibitors [6][33]. - The collaboration with AstraZeneca for the pan-KRAS inhibitor JAB-23E73 is expected to accelerate the global value realization of the company's pipeline [5][6][7]. - The company is advancing its ADC platforms, with tADC utilizing KRAS inhibitors as payloads and iADC using STING agonists, aiming to address challenges in traditional therapies [5][6][7]. Market Position and Competitive Landscape - The company is positioned to leverage its innovative drug development capabilities in the oncology sector, particularly with its KRAS-targeted therapies [5][6][7]. - The competitive landscape for pan-KRAS inhibitors is evolving, with the company’s JAB-23E73 showing promising clinical data and safety profiles compared to competitors [5][6][7].